In 1957, Baker moved to Atlanta to help organize Martin Luther King’s new organization, the Southern Christian Leadership Conference (SCLC). A pivotal moment for her was February 1, 1960 when four students from North Carolina A&T University were denied service + said "enough" and sat in.
December 15, 2025 at 2:12 PM
In 1957, Baker moved to Atlanta to help organize Martin Luther King’s new organization, the Southern Christian Leadership Conference (SCLC). A pivotal moment for her was February 1, 1960 when four students from North Carolina A&T University were denied service + said "enough" and sat in.
A new review crystallizes an emerging consensus that dormant lung cancer cells are not just quiescent passengers but epigenetically programmed survivors that drive minimal residual disease, therapeutic resistance, and relapse in both SCLC and NSCLC. #lungcancer
Unlocking Lung Cancer Cell Dormancy: An Epigenetic Perspective
This review summarizes current advances in understanding the epigenetic regulation of cellular dormancy in lung cancer, with a particular emphasis on the interplay between epigenetic modifiers and oncogenic signaling pathways.
www.mdpi.com
December 14, 2025 at 3:01 PM
A new review crystallizes an emerging consensus that dormant lung cancer cells are not just quiescent passengers but epigenetically programmed survivors that drive minimal residual disease, therapeutic resistance, and relapse in both SCLC and NSCLC. #lungcancer
She co-founded the Southern Christian Leadership Conference (SCLC).
She established the Student Nonviolent Coordinating Committee (SNCC).
She played a pivotal role in the National Association for the Advancement of Colored People (NAACP).
She established the Student Nonviolent Coordinating Committee (SNCC).
She played a pivotal role in the National Association for the Advancement of Colored People (NAACP).
December 14, 2025 at 1:24 PM
She co-founded the Southern Christian Leadership Conference (SCLC).
She established the Student Nonviolent Coordinating Committee (SNCC).
She played a pivotal role in the National Association for the Advancement of Colored People (NAACP).
She established the Student Nonviolent Coordinating Committee (SNCC).
She played a pivotal role in the National Association for the Advancement of Colored People (NAACP).
Baker was the driving force behind the creation of the Student Nonviolent Coordinating Committee. In 1960, she organized a conference at Shaw University for student leaders of the sit-in movement. She encouraged them to form their own student-run organization rather than a youth wing of the SCLC. /5
December 14, 2025 at 1:49 AM
Baker was the driving force behind the creation of the Student Nonviolent Coordinating Committee. In 1960, she organized a conference at Shaw University for student leaders of the sit-in movement. She encouraged them to form their own student-run organization rather than a youth wing of the SCLC. /5
This week’s #OncFive 5⃣:
✅ @fda.gov approval for niraparib/abiraterone in BRCA2+ mCSPC
🔎Priority review for nivolumab+AVD in HL
📈Durable toripalimab OS in NPC
🛑Phase 3 GI setback
🟢Orphan drug status granted to a novel ADC for SCLC
Learn more 🔗: www.onclive.com/view/the-onc...
✅ @fda.gov approval for niraparib/abiraterone in BRCA2+ mCSPC
🔎Priority review for nivolumab+AVD in HL
📈Durable toripalimab OS in NPC
🛑Phase 3 GI setback
🟢Orphan drug status granted to a novel ADC for SCLC
Learn more 🔗: www.onclive.com/view/the-onc...
December 13, 2025 at 4:19 PM
This week’s #OncFive 5⃣:
✅ @fda.gov approval for niraparib/abiraterone in BRCA2+ mCSPC
🔎Priority review for nivolumab+AVD in HL
📈Durable toripalimab OS in NPC
🛑Phase 3 GI setback
🟢Orphan drug status granted to a novel ADC for SCLC
Learn more 🔗: www.onclive.com/view/the-onc...
✅ @fda.gov approval for niraparib/abiraterone in BRCA2+ mCSPC
🔎Priority review for nivolumab+AVD in HL
📈Durable toripalimab OS in NPC
🛑Phase 3 GI setback
🟢Orphan drug status granted to a novel ADC for SCLC
Learn more 🔗: www.onclive.com/view/the-onc...
#OTD we honor Ella Baker, a key strategist of the Civil Rights Movement who helped build the NAACP, SCLC and SNCC. She believed in grassroots power and collective leadership. #TheMarchContinues
December 13, 2025 at 3:00 PM
#OTD we honor Ella Baker, a key strategist of the Civil Rights Movement who helped build the NAACP, SCLC and SNCC. She believed in grassroots power and collective leadership. #TheMarchContinues
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell #LungCancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). www.ejcancer.com/article/S095...
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open...
Small cell lung cancer (SCLC) is an aggressive tumour type accounting for 10–15 %
of lung cancers. The role of thoracic radiotherapy (TRT) in extensive stage SCLC (ES_SCLC)
in the era of checkpoint in...
www.ejcancer.com
December 11, 2025 at 12:05 PM
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell #LungCancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). www.ejcancer.com/article/S095...
a leading international expert as he unpacks the science driving the next wave of change in SCLC.
📅 Date: March 20
⏰ Time: 10:00AM - 4:30PM
📍 Location: Novotel Melbourne on Collins
Register now > buff.ly/WEOKZ9Z
📅 Date: March 20
⏰ Time: 10:00AM - 4:30PM
📍 Location: Novotel Melbourne on Collins
Register now > buff.ly/WEOKZ9Z
December 11, 2025 at 5:30 AM
a leading international expert as he unpacks the science driving the next wave of change in SCLC.
📅 Date: March 20
⏰ Time: 10:00AM - 4:30PM
📍 Location: Novotel Melbourne on Collins
Register now > buff.ly/WEOKZ9Z
📅 Date: March 20
⏰ Time: 10:00AM - 4:30PM
📍 Location: Novotel Melbourne on Collins
Register now > buff.ly/WEOKZ9Z
S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM
December 8, 2025 at 2:40 PM
S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM
Once considered a uniformly lethal disease with limited treatment options, SCLC is now at the brink of change.
Through case studies and discussion, the program will cover evolving standards of care, practical approaches to management, and opportunities for clinical research.
Through case studies and discussion, the program will cover evolving standards of care, practical approaches to management, and opportunities for clinical research.
December 5, 2025 at 1:12 AM
Once considered a uniformly lethal disease with limited treatment options, SCLC is now at the brink of change.
Through case studies and discussion, the program will cover evolving standards of care, practical approaches to management, and opportunities for clinical research.
Through case studies and discussion, the program will cover evolving standards of care, practical approaches to management, and opportunities for clinical research.
REGISTRATIONS OPEN for our SCLC Masterclass
We are excited to welcome our Chairs for this Masterclass: A/Prof Surein Arulananda and Dr Rebecca Tay
Register Now with an Early Bird Ticket buff.ly/Y7gaqCn
We are excited to welcome our Chairs for this Masterclass: A/Prof Surein Arulananda and Dr Rebecca Tay
Register Now with an Early Bird Ticket buff.ly/Y7gaqCn
December 5, 2025 at 1:12 AM
REGISTRATIONS OPEN for our SCLC Masterclass
We are excited to welcome our Chairs for this Masterclass: A/Prof Surein Arulananda and Dr Rebecca Tay
Register Now with an Early Bird Ticket buff.ly/Y7gaqCn
We are excited to welcome our Chairs for this Masterclass: A/Prof Surein Arulananda and Dr Rebecca Tay
Register Now with an Early Bird Ticket buff.ly/Y7gaqCn
A federal judge has denied the early unsealing of decades-old FBI surveillance files involving Rev. Martin Luther King Jr., Bernard S. Lee, and the Southern Christian Leadership Conference (SCLC), according to a joint statement from SCLC.
FBI surveillance files on MLK to remain sealed, judge rules
A federal judge denied early release of FBI surveillance files on Martin Luther King Jr., siding with his family’s privacy concerns.
amsterdamnews.com
December 4, 2025 at 6:14 PM
A federal judge has denied the early unsealing of decades-old FBI surveillance files involving Rev. Martin Luther King Jr., Bernard S. Lee, and the Southern Christian Leadership Conference (SCLC), according to a joint statement from SCLC.
#OTD in 1967, SCLC announced a historic campaign: direct, nonviolent protest in Washington to confront poverty and inequality. Dr. King urged all Americans of goodwill to join the Poor People's Campaign, uniting Black, Brown, and all poor Americans.
December 4, 2025 at 6:13 PM
#OTD in 1967, SCLC announced a historic campaign: direct, nonviolent protest in Washington to confront poverty and inequality. Dr. King urged all Americans of goodwill to join the Poor People's Campaign, uniting Black, Brown, and all poor Americans.
The strategy of SCLC was to remain nonviolent but persistent and in-your-face, knowing the authorities would escalate to violence, and that would get public attention with sympathy for the nonviolent victims. It revealed the systematic violence in a racist society.
December 2, 2025 at 3:07 PM
The strategy of SCLC was to remain nonviolent but persistent and in-your-face, knowing the authorities would escalate to violence, and that would get public attention with sympathy for the nonviolent victims. It revealed the systematic violence in a racist society.
#PCBCommunity |🫁 #NuageTx obté 2,7 M€ de @ageinves.bsky.social per impulsar el desenvolupament del #fàrmac NTX-A, dirigit al subtipus més comú del #càncer de pulmó de cèl·lules petites #SCLC-A. 👨🔬El projecte es desenvolupa en consorci amb @cniostopcancer.bsky.social, @embl.org i el @vhio.bsky.social.
Nuage Therapeutics obté 2,7 M€ per al desenvolupament d’una teràpia pionera contra el càncer de pulmó més agressiu - Parc Científic de Barcelona
El finançament de 2,7 milions d’euros permetrà accelerar el desenvolupament del fàrmac NTX-A fins a la fase clínica.
www.pcb.ub.edu
December 2, 2025 at 10:49 AM
#PCBCommunity |🫁 #NuageTx obté 2,7 M€ de @ageinves.bsky.social per impulsar el desenvolupament del #fàrmac NTX-A, dirigit al subtipus més comú del #càncer de pulmó de cèl·lules petites #SCLC-A. 👨🔬El projecte es desenvolupa en consorci amb @cniostopcancer.bsky.social, @embl.org i el @vhio.bsky.social.
In the rush of the season, don’t forget to care for yourself, too.
Wishing you a weekend filled with rest, recovery, and reconnection!
#TakeCare #SeasonOfGratitude #TakeAMoment #sclc
Wishing you a weekend filled with rest, recovery, and reconnection!
#TakeCare #SeasonOfGratitude #TakeAMoment #sclc
November 28, 2025 at 5:34 PM
In the rush of the season, don’t forget to care for yourself, too.
Wishing you a weekend filled with rest, recovery, and reconnection!
#TakeCare #SeasonOfGratitude #TakeAMoment #sclc
Wishing you a weekend filled with rest, recovery, and reconnection!
#TakeCare #SeasonOfGratitude #TakeAMoment #sclc
📰New & Featured | A study in #Nature: #POU2F3 forms a DNA-dependent complex with #OCA-T1 or #OCA-T2
🔸Suppression of POU2F3/OCA-T1 results in tuft cell-like #SCLC xenograft regression
🔸Vulnerabilities in #POU2F3-OCA-T complex that might be susceptible to therapeutic disruption
🔸Suppression of POU2F3/OCA-T1 results in tuft cell-like #SCLC xenograft regression
🔸Vulnerabilities in #POU2F3-OCA-T complex that might be susceptible to therapeutic disruption
November 27, 2025 at 11:01 PM
5/n
This discovery positions Menin inhibitors as a promising new therapeutic strategy for SCLC. The Burr Lab is now working to translate these insights toward clinical trials, with the goal of bringing more effective and durable treatments to people affected by this aggressive cancer.
This discovery positions Menin inhibitors as a promising new therapeutic strategy for SCLC. The Burr Lab is now working to translate these insights toward clinical trials, with the goal of bringing more effective and durable treatments to people affected by this aggressive cancer.
November 27, 2025 at 3:06 PM
5/n
This discovery positions Menin inhibitors as a promising new therapeutic strategy for SCLC. The Burr Lab is now working to translate these insights toward clinical trials, with the goal of bringing more effective and durable treatments to people affected by this aggressive cancer.
This discovery positions Menin inhibitors as a promising new therapeutic strategy for SCLC. The Burr Lab is now working to translate these insights toward clinical trials, with the goal of bringing more effective and durable treatments to people affected by this aggressive cancer.
3/n
In a 2023 Nature Cell Biology study (www.nature.com/articles/s41...), the team uncovered how a special class of genes known as bivalent genes are misregulated in small cell lung cancer (SCLC).
In a 2023 Nature Cell Biology study (www.nature.com/articles/s41...), the team uncovered how a special class of genes known as bivalent genes are misregulated in small cell lung cancer (SCLC).
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes - Nature Cell Biology
With whole-genome screens using a bivalent MHC class I gene expression readout, Sparbier et al. identify opposing roles for Menin and KMT2A/B in modulating activating H3K4me3 versus repressive H3K27me...
www.nature.com
November 27, 2025 at 3:06 PM
3/n
In a 2023 Nature Cell Biology study (www.nature.com/articles/s41...), the team uncovered how a special class of genes known as bivalent genes are misregulated in small cell lung cancer (SCLC).
In a 2023 Nature Cell Biology study (www.nature.com/articles/s41...), the team uncovered how a special class of genes known as bivalent genes are misregulated in small cell lung cancer (SCLC).
ACT UP was one of the greatest civil rights organizations of the 20th century—not on the same level as the SCLC or SNCC—but still an incredibly brave group of people who helped create a sea change for the rights of marginalized people in the US.
November 26, 2025 at 7:40 PM
ACT UP was one of the greatest civil rights organizations of the 20th century—not on the same level as the SCLC or SNCC—but still an incredibly brave group of people who helped create a sea change for the rights of marginalized people in the US.
We are grateful for our community and the opportunity to serve you each year! 🍂🧡
A quick reminder: we will be closed on Thanksgiving Day and the following Friday. Have a safe and restful holiday weekend!
#sclc #holidayseason #grateful #community
A quick reminder: we will be closed on Thanksgiving Day and the following Friday. Have a safe and restful holiday weekend!
#sclc #holidayseason #grateful #community
November 26, 2025 at 5:04 PM
We are grateful for our community and the opportunity to serve you each year! 🍂🧡
A quick reminder: we will be closed on Thanksgiving Day and the following Friday. Have a safe and restful holiday weekend!
#sclc #holidayseason #grateful #community
A quick reminder: we will be closed on Thanksgiving Day and the following Friday. Have a safe and restful holiday weekend!
#sclc #holidayseason #grateful #community
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgen
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy
www.amgen.com
November 26, 2025 at 3:02 PM
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
Today we answer the call to make a difference. 💙
On #GivingTuesday, your support fuels our mission to uplift Sacramento’s diverse communities through culture, language, and compassion. Together, we make impact possible.
#community #sclc #support
On #GivingTuesday, your support fuels our mission to uplift Sacramento’s diverse communities through culture, language, and compassion. Together, we make impact possible.
#community #sclc #support
November 25, 2025 at 10:50 PM
Today we answer the call to make a difference. 💙
On #GivingTuesday, your support fuels our mission to uplift Sacramento’s diverse communities through culture, language, and compassion. Together, we make impact possible.
#community #sclc #support
On #GivingTuesday, your support fuels our mission to uplift Sacramento’s diverse communities through culture, language, and compassion. Together, we make impact possible.
#community #sclc #support
... situate Brown in the Cold War moment but also establish massive resistance as a baseline before getting into Montgomery, SCLC, sit ins and SNCC; rerun the MLK timeline but democratize it with recent work; embed affirmative action in the movement, highlight King's later radicalism ...
November 25, 2025 at 12:36 AM
... situate Brown in the Cold War moment but also establish massive resistance as a baseline before getting into Montgomery, SCLC, sit ins and SNCC; rerun the MLK timeline but democratize it with recent work; embed affirmative action in the movement, highlight King's later radicalism ...
The @FDA has fully approved tarlatamab (Imdelltra®), a targeted immunotherapy for adults with advanced small cell #lungcancer (#SCLC) that has progressed after platinum-based chemo.
The approval is based on an international phase 3 trial led by MSK’s Dr. Charles Rudin.
Learn more: bit.ly/44vKjYm
The approval is based on an international phase 3 trial led by MSK’s Dr. Charles Rudin.
Learn more: bit.ly/44vKjYm
FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based on Trial Led by MSK Researcher
The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial le...
bit.ly
November 24, 2025 at 6:22 PM
The @FDA has fully approved tarlatamab (Imdelltra®), a targeted immunotherapy for adults with advanced small cell #lungcancer (#SCLC) that has progressed after platinum-based chemo.
The approval is based on an international phase 3 trial led by MSK’s Dr. Charles Rudin.
Learn more: bit.ly/44vKjYm
The approval is based on an international phase 3 trial led by MSK’s Dr. Charles Rudin.
Learn more: bit.ly/44vKjYm